Press Releases

Flagship Pioneering and its portfolio companies make news because of their transformative approaches to solving global challenges. If you have needs beyond these resources, please contact press@flagshippioneering.com.

company

year

domain

Otsuka Pharmaceutical to Acquire Visterra

Visterra 07.11.2018

FDA Grants Fast Track Designation to Visterra’s VIS410 for Treatment of Hospitalized Patients with Influenza A

Visterra 11.01.2017

Visterra Announces Research Collaboration, Exclusive License, and Option Agreement for Infectious Diseases with Vir Biotechnology

Visterra 10.18.2017

Visterra Awarded CARB-X Contract to Advance Development of VIS705

Visterra 03.30.2017

Visterra Doses First Patient in Phase 2a Trial for VIS410, its Monoclonal Antibody in Development for the Treatment of Hospitalized Patients with Influenza A

Visterra 01.11.2017

Visterra Appoints Two Industry Leaders to its Board of Directors

Visterra 04.21.2016

Visterra’s Monoclonal Antibody in Development for the Treatment of Influenza A, VIS410, Demonstrated Significant Antiviral Activity and Reduced Duration of Respiratory Symptoms in Phase 2a Challenge Study

Visterra 10.05.2015

Visterra Awarded Contract Valued at up to $204.5 Million to Advance the Development of VIS410, its Novel Monoclonal Antibody for the Treatment of Influenza A, by the Biomedical Advanced Research and Development Authority (BARDA)

Visterra 10.05.2015

Visterra, Inc. and Serum Institute of India Ltd. Announce Collaboration to Advance VIS513, a Monoclonal Antibody in Development for the Treatment of Dengue, in the Indian Subcontinent

Visterra 09.09.2015

Loading